Aims: In this multicentre prospective registry we sought to evaluate the immediate and
midterm clinical outcomes following single or multiple overlapping bioresorbable vascular …

Background The bioresorbable vascular scaffold (BVS) technology may be an appealing
option in ST-segment elevation myocardial infarction (STEMI) patients. However, the …

Background—Bioresorbable vascular scaffolds (BVS) represent promising new technology,
but data on their long-term outcomes in ST-segment–elevation myocardial infarction …

Methods Design and mid-term results of BVS STEMI STRATEGY-IT (NCT02601781) were
described elsewhere. 9, 10 The decision to prolong DAPT beyond 1 year was initially left to …

Aims: Early clinical results after implantation of bioresorbable vascular scaffolds (BVS) in ST-
elevation myocardial infarction (STEMI) are encouraging, but long-term data are missing …

Background Bioresorbable vascular scaffold (BRS) technology appears to be an appealing
option in ST-elevation myocardial infarction (STEMI) patients. The available evidence on …

Background Newer-generation DES may be considered the standard of care for the
treatment of STEMI patients undergoing primary PCI. However, the implantation of these …

Aims Recent studies have demonstrated favourable clinical outcomes for the everolimus-
eluting bioresorbable vascular scaffold (BVS) ABSORB™ in patients with stable coronary …

Abstract Aims Bioresorbable vascular scaffolds (BVSs) have been studied in chronic
coronary artery disease, but not in acute ST-segment elevation myocardial infarction …

Background: Bioresorbable vascular scaffolds (BVS) implantation in selected patients with
stable angina has been demonstrated feasible and safe. However, limited data are currently …